MetaCap

InfuSystems (INFU) vs Profound Medical (PROF)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

InfuSystems (INFU) has outperformed Profound Medical (PROF) over the past year, gaining 51.7% versus a gain of 6.2%. Over five years, INFU leads with a -15.9% price change compared with -43.6% for PROF. InfuSystems is the larger company by market cap ($287.5 million vs $233.7 million), about 1.2 times the size, while Profound Medical is growing revenue faster (+50.7% vs +6.4%).

InfuSystems converts more of its revenue into profit, with a net margin of 4.6% versus -264.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INFU+51.69%PROF+6.16%
+66%+20%-26%
Nov 21, 20251 yearNov 20, 2026
INFU-19.70%PROF-47.62%
+27%-25%-78%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INFU versus PROF key metrics
MetricINFUPROF
Share price$14.35$6.38
Market cap$287.48M$233.68M
1-day change+2.06%-3.19%
YTD return+59.98%-18.93%
1-year return+51.69%+6.16%
5-year return-15.93%-43.64%
P/E ratio (TTM)32.61—
Forward P/E25.63—
EPS (TTM)$0.44$-0.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$143.44M$16.10M
Revenue growth (YoY)+6.36%+50.73%
Net income (latest FY)$6.63M$-42.57M
Gross margin55.98%70.77%
Operating margin8.31%-256.27%
Net margin4.62%-264.44%
52-week high$15.47$8.95
52-week low$7.29$4.80
Distance from 52-week high-7.24%-28.72%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+28.92%+74.61%
Average volume136.60K208.29K
Shares outstanding20.03M36.63M
Employees461162
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INFU has outperformed PROF by 45.5 percentage points over the past year.
  • InfuSystems is more profitable, keeping 4.6 cents of every revenue dollar as net income versus -264.4 cents for Profound Medical.
  • Profound Medical grew revenue faster in its latest fiscal year (+50.73% vs +6.36%).

About InfuSystems

INFU stock →

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions.

Health Care · Medical/Dental Instruments · 461 employees

About Profound Medical

PROF stock →

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.

Health Care · Medical/Dental Instruments · 162 employees

INFU vs PROF FAQ

Which is bigger, InfuSystems or Profound Medical?

InfuSystems (INFU) is larger, with a market capitalization of $287.48M compared with $233.68M for Profound Medical (PROF).

Which stock has performed better over the past year, INFU or PROF?

INFU returned +51.69% over the past 12 months, compared with +6.16% for PROF (price return, excluding dividends). Past performance does not predict future results.

Are InfuSystems and Profound Medical in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons